Our results here did indicate that the combined treatment with GPC3-28z CAR-T cells and GPC3-Syn-IL12 NK92 cells had better antitumor activities than the single drug treatment in mice bearing GPC3-positive tumor xenografts. The gene discussed is GPC3; the disease is neoplasm.